UPMC Hillman Cancer Center, 5150 Centre Avenue, 5th floor, Room 552, Pittsburgh, PA, 15232, USA.
Curr Treat Options Oncol. 2018 Oct 27;19(12):68. doi: 10.1007/s11864-018-0587-0.
In head and neck cancer, we continue to work towards a more personalized approach to treatment of patients, where analysis of a patient's tumor guides targeting of molecular or immunologic pathways. Critically important to this pursuit is a better understanding of the direct biologic effect of a drug or combination on the tumor microenvironment in humans, as well as biomarker discovery. These goals are consistent with the primary purpose of a "window of opportunity" trial and while conduct of these trials requires a careful balance of benefits and potential risks, to date these trials have been both feasible and safe in HNSCC in the curative intent setting. In the era of immunotherapy, with countless possible combinations and ongoing clinical trials, window trials are even more important for informing clinical trial design and appropriate combination therapy, and ultimately a more personalized approach to our patients that leads to improvement in outcomes.
在头颈部癌症中,我们继续朝着更个体化的治疗方法努力,即根据患者肿瘤的分析来指导靶向分子或免疫途径。这项工作的关键是更好地了解药物或联合用药对人类肿瘤微环境的直接生物学作用,以及生物标志物的发现。这些目标与“机会之窗”试验的主要目的一致,虽然这些试验的进行需要仔细平衡收益和潜在风险,但迄今为止,在根治性治疗中,这些试验对头颈部鳞状细胞癌是可行且安全的。在免疫治疗时代,有无数可能的组合和正在进行的临床试验,因此“机会之窗”试验对于为临床试验设计和适当的联合治疗提供信息,以及最终为我们的患者提供更个性化的治疗方法,从而改善治疗结果更为重要。